# Vifor Pharma

**Type:** Funders  
**Canonical URL:** https://scholariq.org/funders/vifor-pharma/

## Facts

| Field | Value |
| --- | --- |
| Country | CH |
| Description | company in Glattbrugg, Switzerland |
| OpenAlex ID | https://openalex.org/F4320323906 |
| ROR ID | https://ror.org/0185z7g17 |
| Works | 2,081 |

## Funder papers

Showing 15 of 16.

- [Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction](https://scholariq.org/papers/angiotensin-neprilysin-inhibition-in-heart-failure-with-preserved-ejection/)
- [Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial](https://scholariq.org/papers/safety-and-tolerability-of-the-novel-non-steroidal-mineralocorticoid-receptor/)
- [A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease](https://scholariq.org/papers/a-randomized-controlled-study-of-finerenone-vs-eplerenone-in-patients-with/)
- [Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial](https://scholariq.org/papers/patiromer-for-the-management-of-hyperkalemia-in-heart-failure-with-reduced/)
- [Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF](https://scholariq.org/papers/initial-decline-dip-in-estimated-glomerular-filtration-rate-after-initiation-of/)
- [Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists](https://scholariq.org/papers/dapagliflozin-in-hfref-patients-treated-with-mineralocorticoid-receptor/)
- [The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study](https://scholariq.org/papers/the-effect-of-intravenous-ferric-carboxymaltose-on-health-related-quality-of/)
- [A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease](https://scholariq.org/papers/a-comparative-post-hoc-analysis-of-finerenone-and-spironolactone-in-resistant/)
- [Changes in Echocardiographic Parameters in Iron Deficiency Patients with Heart Failure and Chronic Kidney Disease Treated with Intravenous Iron](https://scholariq.org/papers/changes-in-echocardiographic-parameters-in-iron-deficiency-patients-with-heart/)
- [Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the <scp>EMPULSE</scp> trial](https://scholariq.org/papers/renal-effects-of-empagliflozin-in-patients-hospitalized-for-acute-heart-failure/)
- [Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial](https://scholariq.org/papers/vericiguat-in-patients-with-chronic-heart-failure-and-reduced-ejection-fraction/)
- [Patiromer Versus Placebo to Enable Spironolactone Use in Patients with Resistant Hypertension and Chronic Kidney Disease ( <b>AMBER</b> ): Results in the Pre-Specified Subgroup with Heart Failure](https://scholariq.org/papers/patiromer-versus-placebo-to-enable-spironolactone-use-in-patients-with-resistant-2/)
- [Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis](https://scholariq.org/papers/spironolactone-in-patients-on-chronic-haemodialysis-at-high-risk-of-adverse/)
- [Ferric Carboxymaltose in Iron-Deficient Patients with Hospitalized Heart Failure and Reduced Kidney Function](https://scholariq.org/papers/ferric-carboxymaltose-in-iron-deficient-patients-with-hospitalized-heart-failure/)
- [Patiromer-Facilitated Renin-Angiotensin-Aldosterone System Inhibitor Utilization in Patients with Heart Failure with or without Comorbid Chronic Kidney Disease: Subgroup Analysis of DIAMOND Randomized Trial](https://scholariq.org/papers/patiromer-facilitated-renin-angiotensin-aldosterone-system-inhibitor-utilization/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.